NANOVALENT PHARMACEUTICALS INC
Bozeman, MT · Biotech · Private
Blood-brain barrier penetrating nanoparticles encapsulating cytotoxic drugs for brain tumor treatment
- Grants
- $11M
- 15 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 3 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions | $238,728 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions | $238,728 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Nanoparticle Delivery System for Ewing Sarcoma Treatment | $240,750 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Nanoparticle Delivery System for Ewing Sarcoma Treatment | $240,750 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | $831,190 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | $1,590,480 | |
| Federal grant | Department of Health and Human Services · Phase II · NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | $240,749 | |
| Federal grant | Department of Health and Human Services · Phase II · NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | $1,019,254 | |
| Federal grant | Department of Health and Human Services · Phase II · NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | $1,912,023 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | $759,290 | |
| Federal grant | Department of Health and Human Services · Phase II · NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | $892,769 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | $400,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2762 | VIRTUS THERAPEUTICS CORPORATION | — | — |
| 2763 | SPECIFICA, INC. | — | — |
| 2764 | SAFI BIOTHERAPEUTICS INC | — | — |
| 2765 | NANOVALENT PHARMACEUTICALS INC | — | — |
| 2766 | Florey Biosciences, Inc. | — | $1.4M |
| 2767 | JSK THERAPEUTICS INC. | — | $963K |
| 2768 | Wave Bye Inc. | — | $852K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Targeted Polymerized Nanoparticles For Cancer Treatmentgranted
- Targeted Polymerized Nanoparticles For Cancer Treatmentapplication
- Targeted Polymerized Nanoparticles For Cancer Treatmentgranted
- Compositions And Methods For Treating Ewing Sarcomagranted
- Targeted Polymerized Nanoparticles For Cancer Treatmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.